- Home
- NYXH vs ACIU Comparison
NYXH vs ACIU Comparison
Compare NYXH & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NYXH
- ACIU
- Stock Information
- Founded
- NYXH 2009
- ACIU 2003
- Country
- NYXH Belgium
- ACIU Switzerland
- Employees
- NYXH N/A
- ACIU N/A
- Industry
- NYXH Medical/Dental Instruments
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- NYXH Health Care
- ACIU Health Care
- Exchange
- NYXH Nasdaq
- ACIU Nasdaq
- Market Cap
- NYXH 261.1M
- ACIU 305.7M
- IPO Year
- NYXH 2021
- ACIU 2016
- Fundamental
- Price
- NYXH $8.22
- ACIU $3.19
- Analyst Decision
- NYXH Strong Buy
- ACIU Strong Buy
- Analyst Count
- NYXH 5
- ACIU 2
- Target Price
- NYXH $17.00
- ACIU $12.00
- AVG Volume (30 Days)
- NYXH 26.6K
- ACIU 140.1K
- Earning Date
- NYXH 11-06-2024
- ACIU 11-05-2024
- Dividend Yield
- NYXH N/A
- ACIU N/A
- EPS Growth
- NYXH N/A
- ACIU N/A
- EPS
- NYXH N/A
- ACIU N/A
- Revenue
- NYXH $5,668,079.00
- ACIU $48,505,404.00
- Revenue This Year
- NYXH $37.10
- ACIU N/A
- Revenue Next Year
- NYXH $418.12
- ACIU $938.44
- P/E Ratio
- NYXH N/A
- ACIU N/A
- Revenue Growth
- NYXH 32.65
- ACIU 4097200.00
- 52 Week Low
- NYXH $4.00
- ACIU $2.25
- 52 Week High
- NYXH $20.00
- ACIU $5.14
- Technical
- Relative Strength Index (RSI)
- NYXH 30.23
- ACIU 50.14
- Support Level
- NYXH $8.10
- ACIU $2.80
- Resistance Level
- NYXH $10.01
- ACIU $3.88
- Average True Range (ATR)
- NYXH 0.47
- ACIU 0.22
- MACD
- NYXH -0.19
- ACIU 0.04
- Stochastic Oscillator
- NYXH 6.28
- ACIU 36.11
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.